Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 3/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | TPO | P07202 | 1/20 | 0.43 |
| ▸ | EPX | P11678 | 1/20 | 0.43 |
| ▸ | LPO | P22079 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 9/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | PRKACA | P17612 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23888645 | 0.88 | MPO (0.43) | ASIC3CYP11B1CYP11B2FYNMPO | |
| SCHEMBL30086973 | 0.88 | MPO (0.43) | ASIC3CYP11B1CYP11B2FYNMPO | |
| SCHEMBL23900811 | 0.87 | LOXL2 (0.49) | CYP11B1CYP11B2MPOTPOEPX | |
| SCHEMBL23900459 | 0.86 | CDK8 (0.50) | MPOTPOEPXLPOLTA4H | |
| SCHEMBL23900669 | 0.85 | MPO (0.43) | MPOTPOEPXLPOCDK8 | |
| SCHEMBL16028312 | 0.84 | MPO (0.42) | CYP11B1CYP11B2FYNMPOTPO | |
| SCHEMBL1891053 | 0.83 | ASIC3 (0.59) | ASIC3CYP11B1CYP11B2NPC1RAB9A | |
| SCHEMBL16028774 | 0.83 | DYRK1A (0.44) | MPOTPOEPXLPOLTA4H | |
| SCHEMBL23888712 | 0.82 | MTOR (0.41) | MPOTPOEPXLPOLTA4H | |
| SCHEMBL30086931 | 0.82 | MTOR (0.41) | MPOTPOEPXLPOLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174513-A1 | AMIDE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2023-06-08 | — | — | US | disclosed |
| US-20230174513-A1 | AMIDE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2023-06-08 | — | — | US | disclosed |
| WO-2021197276-A1 | Amide compounds and uses thereof | HUTCHISON MEDIPHARMA LIMITED (CN) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174513-A1 | AMIDE COMPOUNDS AND USES THEREOF | ASNS, ASS1, NAT1 | ASIC3 1047/4885CYP11B1 226/4885CYP11B2 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.